Related Experiment Videos
Studies of cellular immunity in Graves' disease
Endocrinologie
|October 1, 1983
Summary
Graves' disease patients showed low T-lymphocyte counts. The leucocyte inhibition factor (LIF) test revealed significant lymphocyte sensitization in patients with relapsed thyrotoxicosis, suggesting its use in monitoring treatment.
Area of Science:
- Immunology
- Endocrinology
- Cellular Biology
Background:
- Graves' disease and thyrotoxicosis involve immune system dysregulation.
- Cellular immunity, particularly T-lymphocyte function, plays a role in autoimmune thyroid conditions.
- Understanding immune responses is crucial for managing thyrotoxicosis and its relapses.
Purpose of the Study:
- To investigate cellular immunity aspects in untreated Graves' disease and relapsed thyrotoxicosis.
- To evaluate T-lymphocyte counts and lymphocyte sensitization using the leucocyte inhibition factor (LIF) test.
- To explore the potential of the LIF test in predicting thyrotoxicosis relapse after drug therapy cessation.
Main Methods:
- Studied patients with untreated Graves' disease and those experiencing relapse after anti-thyroid drug withdrawal.
- Measured peripheral blood T-lymphocyte counts.
- Performed leucocyte inhibition factor (LIF) tests to assess lymphocyte sensitization to thyroglobulin and microsomal antigen.
Main Results:
- Untreated patients exhibited significantly lower T-lymphocyte counts.
- A slight lymphocyte sensitization to thyroglobulin was observed in untreated patients.
- Marked lymphocyte sensitization to thyroglobulin and microsomal antigen was evident in relapsed thyrotoxicosis patients via LIF test.
Conclusions:
- Some untreated Graves' disease patients display lymphocyte function abnormalities.
- Intense lymphocyte sensitization in the LIF test indicates a high likelihood of thyrotoxicosis relapse.
- The LIF test may serve as a valuable indicator for predicting thyrotoxicosis recurrence after discontinuing anti-thyroid medication.